CN104688970A - Drug combination particles having function of losing weight and preparation method thereof - Google Patents
Drug combination particles having function of losing weight and preparation method thereof Download PDFInfo
- Publication number
- CN104688970A CN104688970A CN201510121932.6A CN201510121932A CN104688970A CN 104688970 A CN104688970 A CN 104688970A CN 201510121932 A CN201510121932 A CN 201510121932A CN 104688970 A CN104688970 A CN 104688970A
- Authority
- CN
- China
- Prior art keywords
- moringa
- granule
- rhizoma amorphophalli
- leaf
- amorphophalli powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention relates to drug combination particles having a function of losing weight, and a preparation method thereof. The drug combination particles having the function of losing weight are prepared by the following raw material medicines: 0.1-10 parts by weight of konjaku flour, and 1 part by weight of horseradish tree leaves. The two raw material medicines are prepared into particles after being combined according to the formula ratio. The drug combination particles having the function of losing weight are of a synergistic interaction effect; the curative effect can be increased significantly; the dosage of drugs for losing weight is less; the course of treatment is short; the result is quick; and the side effect to the body of the patient is small.
Description
Technical field
The present invention relates to a kind of medicament composition granule with antiobesity action and preparation method thereof, belong to medical art.
Background technology
21 century, obesity has become one of most important public health challenge.Fat closely related with metabolic syndrome (cardiovascular risk factors comprises hypertension, fat metabolic disturbance and insulin resistance), and can the life-span be reduced.According to estimates, have the American of 2/3 overweight or fat, in addition, along with developing country more and more adopts western diet and life style, bariatric patients's quantity will increase further.Estimate according to World Health Organization (WHO), in global range, Overweight and obesity crowd is more than 1,400,000,000.
Current multiple appetrol are quit listing, and doctor's difficulty has more therapeutic choice, and expert claims, the body weight of lasting reduction at least 5%, can reduce obesity and the cardiovascular disease relevant to obesity and diabetes risk.According to the guidance that regulator delivers, reduce 5% minimum standards of just losing weight of body weight, clinician and patient then have higher expectation, and they wish that fat-reducing effect is more obvious, namely at least reduce 10% of body weight.Commercially can the moderate medicine of curative effect in, because its tolerance is poor, safety is low, lack the reasons such as new therapy, inhibit the market development of obesity treatment drugs in itself.And the exploitation of disturbance to this market and new drug of quitting listing one after another of appetrol in recent years makes the matter worse especially.The subject matter of appetrol is its long-term safety.In past 40 years, 5 kinds of appetrol are withdrawn from the market because of potential safety hazard.Wherein, foremost two kinds of medicines are the Pondimin(fenfluramine of Wyeth's (being purchased by Pfizer)) and Redux(dexfenfluramine) withdrew from the market in 1997 years.These two kinds of medicines are found to increase valve disorder risk, and listing is only just withdrawn from the market for 1 year.The appetrol of quitting listing recently have the Meridia/Reductil(sibutramine of Abbott Laboratories), quit listing in 2010 due to cardiovascular disease may be caused; The Mediator(benfluorex of Servier company), owing to quitting listing in 2009 by cardiac trigger valvular heart disease; The Acomplia(Rimonabant of Sai Nuofei), quit listing in 2008 due to depression or suicidal idea may be caused.Most popular phentermine, belongs to the derivant of amphetamines, recent decades because of its cheap but not evident in efficacy or safe and reliable and use.Other conventional fat reduction therapy medicines are lipase inhibitor orlistat (Xenical on market and nonprescription drugs Alli), because orlistat often can cause gastrointestinal upset (as fecal incontinence or oiliness stool), also limit it and use further.But, along with sibutramine quitting listing in Europe, orlistat has become the medicine that this area uniquely may be used for losing weight.
In China market, in January, 2009, due to serious adverse reactions such as meeting cardiac trigger infringements, SFDA requires in China, forbids production and sales and uses fenfluramine hydrochloride tablets and crude drug thereof.On October 30th, 2010, SFDA gives notice, and determine to stop sibutramine preparation and crude drug in the producing and selling of China and use, the medicine of list marketing, is responsible for recalling destruction by manufacturing enterprise.This paper notifies, terminated the sales histories reaching 10 years with " Sibutramine Hydrochloride " the sibutramine series appetrol that are representative in China.
Below be all chemical drugs, life-time service more or less has untoward reaction or toxic and side effects, and some side effect is also very large, although compound Chinese medicinal preparation untoward reaction is less, general validity is poor.So it is few to find untoward reaction, safety, but eutherapeutic natural drug is the problem needing solution badly.
Summary of the invention
The object of the present invention is to provide a kind of medicament composition granule with antiobesity action newly, this medicament composition granule fat-reducing instant effect, good effect and little to person side effect.
Another object of the present invention is to provide a kind of preparation method of aforementioned pharmaceutical compositions granule.
In order to realize foregoing invention object, the invention provides following technical scheme:
Have a medicament composition granule for antiobesity action, be made up of the crude drug of following weight: Rhizoma amorphophalli powder 1 ~ 10 part, leaf of Moringa 1 part, make granule, particle diameter is no more than 5mm.
Preferably, in above-mentioned raw materials medicine proportioning, Rhizoma amorphophalli powder 2 ~ 8 parts, leaf of Moringa 1 part.
Preferred, in above-mentioned raw materials medicine proportioning, Rhizoma amorphophalli powder 3 parts, leaf of Moringa 1 part.
Aforementioned pharmaceutical compositions granule obtains by following methods preparation:
Get Rhizoma amorphophalli powder and the leaf of Moringa crude drug of described proportioning, leaf of Moringa directly pulverized or carries out extraction drying according to a conventional method, then mixing homogeneously with Rhizoma amorphophalli powder, make granule.Pharmaceutically acceptable carrier can be added or/and adjuvant making in granule process, but not add liquid adhesive.
In above-mentioned raw materials medicine: the extraction of substance containing glucomannoglycan (KGM) that Rhizoma amorphophalli powder general reference is extracted from Rhizoma amorphophalli.Have the materials such as Rhizoma amorphophalli powder, konjaku powder, Rhizoma amorphophalli fine powder, Rhizoma amorphophalli fine powder, Rhizoma amorphophalli extract, Konjac glucomannan, glucomannoglycan in the market, these are all included within the Rhizoma amorphophalli powder category of indication of the present invention.Leaf of Moringa is the dry leaves of perennial tropical deciduous tree Moringa tree (being also called drumstick tree), and the Classification system of Moringa is: Moringa Oleifera Lamarch, English by name: Moringa tree.
The instructions of taking of granule of the present invention is directly pour in mouth by dry granule, use mixing in water for oral taking.
compared with prior art, beneficial effect of the present invention: medicament composition granule of the present invention is the granule be made up of Rhizoma amorphophalli powder, leaf of Moringa 2 kinds of raw materials, there is following distinguishing feature: after (1) this granule enters gastric, after contained Rhizoma amorphophalli powder absorbs moisture content under the environment of water, its volume is inflatable to about self 100 times, occupy gastric volume, thus make eater produce satiety, reduce the absorption of food total amount, reach the effect reducing energy intake; (2) in granule, contained leaf of Moringa is nutritious, rich in proteins and various trace elements, compatibility together with Rhizoma amorphophalli powder, owing to forming gelling material after Rhizoma amorphophalli powder chance water, therefore leaf of Moringa Middle nutrition composition slow releasing can be made, slowly absorb, be unlikely to the malnutrition causing food total amount Deficiency of Intake to cause; (3) the more important thing is: also just because of the package action of Rhizoma amorphophalli powder to leaf of Moringa, if both are used in combination simply, to be not easy dispersed in vivo, and directly cause having given play to its due effect, and be difficult to supplement basic nutrition element while fat-reducing; And make after diameter is no more than the granule of 5mm, directly can be placed in oral cavity, pour in stomach with water, be conducive to Rhizoma amorphophalli powder dispersion, and due to each granule be a little slow release unit, be conducive to again the stripping of leaf of Moringa Middle nutrition composition.So, Rhizoma amorphophalli powder, leaf of Moringa compatibility use, it not simple combination, both respective advantage had been taken into full account, improve for weak point again, make curative effect compared with common konjac compositions product, there is apparent synergism, rapid-action, good effect, and without any side effects to patient body.
Detailed description of the invention
Below in conjunction with test example and detailed description of the invention, the present invention is described in further detail.But this should be interpreted as that the scope of the above-mentioned theme of the present invention is only limitted to following embodiment, all technology realized based on content of the present invention all belong to scope of the present invention.
Detailed description of the invention
Below in conjunction with detailed description of the invention, the present invention is described in further detail.
Embodiment 1-5, is grouped into according to one-tenth each in following table 1 and weight proportion makes corresponding medicament composition granule.
Table 1(unit: part)
Each embodiment is all obtained by following preparation method above:
Get the Rhizoma amorphophalli powder of described proportioning, leaf of Moringa and microcrystalline cellulose (filler), first leaf of Moringa is directly ground into smalls, then mixs homogeneously with Rhizoma amorphophalli powder and microcrystalline cellulose, be pressed into press device the granule that diameter is no more than 5mm, obtain final product.
The medicament composition granule that inventor gets above-described embodiment 1-5 gained carries out curative effect on obesity clinical observation.For the ease of comparing the synergistic function between two kinds of crude drug, individually with two kinds of crude drug, make granule according to identical method, its proportioning raw materials is shown in the comparative example 1 and 2 in above-mentioned table 1.
Methods of clinical observation and result as follows:
1, crowd is observed:
Select Body Mass Index BMI(body weight (kilogram)/height (rice
2)) >30(is fat more than 30) and crowd 270 example, be divided into 9 experimental grouies, each experimental group 30 people.
2, instructions of taking:
1st group to the 5th group: the product taken is corresponding embodiment 1 to embodiment 5 respectively, and dose is each 5g, pours granule into oral cavity when taking, and takes after mixing it with water with 500ml warm water, every day Chinese meal and dinner within first 5 minutes, respectively take once, appetite does not control as usual.
Comparative example 1 and comparative example 2: the samely take mode.
7th group: according to the weight proportion identical with embodiment 3, but do not make granule, but make capsule, take 2 every day, each serving being converted into capsule number when taking with 5g(), instructions of taking is: by capsule mixing in water for oral taking, every day Chinese meal and dinner within first 5 minutes, respectively take once, appetite does not control as usual.
6th group: blank group, do not take any product, appetite does not control as usual.
3, efficacy evaluation:
Weigh before taking, weigh after taking 30 days again, the weight that 2 times are reduced using front and back, as evaluation index, calculates the meansigma methods often organizing crowd's loss of weight, and evaluation often organizes performance status.
4, therapeutic effect is shown in following table 2:
Table 2
In table 2, (1) 1-5 group: compare with comparative example 2,
* *p < 0.01; (2) comparative example 1: compare with the 6th group,
※ ※ ※p < 0.01.
Learnt by statistical data in table 2, take the 1-5 group experimenter of medicine of the present invention, take 30 days continuously, fat-reducing effect is best, p < 0.05 or p < 0.01, has significant difference compared with comparative example 2, especially better with the 3rd group of effect.Comparative example 1, compared with the 6th group (blank group), p < 0.05 or p < 0.01, has significant difference, also effective in cure, but muscle power is poor; Illustrate that Rhizoma amorphophalli powder, Moringa compatibility result of use are better, not only lose weight, also significantly improve performance status.7th group is Capsules group, a few inefficacy, and fat-reducing effect organizes zero difference with blank, illustrates to take after making granule just can have beyond thought fat-reducing effect.
Claims (5)
1. there is a medicament composition granule for antiobesity action, it is characterized in that: it is made up of the crude drug of following weight: Rhizoma amorphophalli powder 1 ~ 10 part, and leaf of Moringa 1 part, make granule, particle diameter is no more than 5mm.
2. medicament composition granule according to claim 1, is characterized in that: Rhizoma amorphophalli powder 2 ~ 8 parts, leaf of Moringa 1 part.
3. medicament composition granule according to claim 1, is characterized in that: Rhizoma amorphophalli powder 3 parts, leaf of Moringa 1 part.
4. the preparation method of a medicament composition granule according to claim 1, it is characterized in that: Rhizoma amorphophalli powder and the leaf of Moringa crude drug of getting described proportioning, leaf of Moringa directly pulverized or carries out extraction drying according to a conventional method, then mixing homogeneously with Rhizoma amorphophalli powder, make granule.
5. method according to claim 4, is characterized in that: make in the process of granule and do not add liquid adhesive.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510121932.6A CN104688970A (en) | 2015-03-19 | 2015-03-19 | Drug combination particles having function of losing weight and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510121932.6A CN104688970A (en) | 2015-03-19 | 2015-03-19 | Drug combination particles having function of losing weight and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104688970A true CN104688970A (en) | 2015-06-10 |
Family
ID=53336794
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510121932.6A Pending CN104688970A (en) | 2015-03-19 | 2015-03-19 | Drug combination particles having function of losing weight and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104688970A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107348489A (en) * | 2017-07-27 | 2017-11-17 | 贵阳学院 | Moringa superfine powder, tablet, the preparation method of chewable tablets |
| CN108771080A (en) * | 2018-06-25 | 2018-11-09 | 湖北治铮健康科技有限公司 | A kind of preparation method of blue berry flavor konjaku high dietary-fiber solid beverage |
-
2015
- 2015-03-19 CN CN201510121932.6A patent/CN104688970A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107348489A (en) * | 2017-07-27 | 2017-11-17 | 贵阳学院 | Moringa superfine powder, tablet, the preparation method of chewable tablets |
| CN108771080A (en) * | 2018-06-25 | 2018-11-09 | 湖北治铮健康科技有限公司 | A kind of preparation method of blue berry flavor konjaku high dietary-fiber solid beverage |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102091315B (en) | Ginger and dark plum fruit composition and preparation method thereof, and application of ginger and dark plum fruit composition in preparation of attenuation and synergy medicaments for radiotherapy and chemotherapy of cancers | |
| CN102145158B (en) | Ginger and clove composition, preparation method of ginger and clove composition and use of ginger and clove composition for preparing toxicity-reducing efficacy-improving medicine in cancer radiotherapy and chemotherapy | |
| CN104000197B (en) | A kind of health products or pharmaceutical composition and its production and use of fatigue-relieving | |
| CN101264311B (en) | Natural pharmaceutical composition, its preparation and its attenuation synergistic use in cancer radiotherapy and chemotherapy | |
| WO2014201637A1 (en) | Compound preparation for treating cervical spondylosis with radiculopathy and preparation method therefor | |
| CN103285145A (en) | Pure traditional Chinese medicine preparation for prompting rapid growth of pigs as well as preparation method and application method thereof | |
| JP4397663B2 (en) | Muscle mass increasing agent | |
| CN104688970A (en) | Drug combination particles having function of losing weight and preparation method thereof | |
| WO2014154008A1 (en) | Purgative composition, preparation method therefor and application thereof | |
| CN103610051A (en) | Food, healthcare food or medicine composition with lipid-lowering effect as well as preparation methods and applications thereof | |
| CN104825702A (en) | Composition capable of reducing fat and supplying nutrients and preparation method thereof | |
| CN104721428A (en) | Slimming composite granules and preparing method thereof | |
| CN102068589A (en) | Blood fat reducing and weight losing medicinal composition and preparation method thereof | |
| CN101491605A (en) | Combination with blood sugar reducing function and preparation method thereof | |
| CN104000876A (en) | Composition of mangnolia officinalis and gingerol and application thereof | |
| CN108324874B (en) | Tea substitute for treating gouty arthritis with syndrome of intermingled cold and heat | |
| CN106563076B (en) | Medicine for treating stomach disease and its preparing method | |
| CN109731037A (en) | A kind of pharmaceutical composition and its application promoting gastrointestinal peristalsis | |
| CN107320665A (en) | Treat precocious pharmaceutical composition of child and preparation method thereof | |
| CN102579713B (en) | Traditional Chinese medicine for treating children obesity and preparation method | |
| CN112791166B (en) | Medicinal and edible composition for enhancing muscle performance and relieving exercise-induced fatigue | |
| JPH0733676A (en) | Composition for lowering blood suger value | |
| CN101537147B (en) | Anaesthetic prescription for treating pulmonary tuberculosis and preparation method thereof | |
| CN101347483A (en) | Chinese herbal medicinal composition for treating enterogastric disease and preparation method and use | |
| CN105031354A (en) | Unio margarita capsule used for curing gastroduodenal ulcer and preparation method and application of Unio margarita capsule |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150610 |